

Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Serum Gonadotrophin Formulation

Manufacturer or supplier's details

Company name of supplier : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1B

GHS label elements

Hazard pictograms

Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the un-

born child.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.



Serum Gonadotrophin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 4.0 14.04.2025 5445454-00009 Date of first issue: 20.02.2020

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Gonadotropin, pregnant mare serum	9002-70-4	>= 30 -< 50

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

Contact with dust can cause mechanical irritation or drying of

aolayou

the skin.

Dust contact with the eyes can lead to mechanical irritation. May damage fertility. Suspected of damaging the unborn

child

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

: None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a



Serum Gonadotrophin Formulation

Date of last issue: 04.12.2024 Version Revision Date: SDS Number: 4.0 14.04.2025 5445454-00009 Date of first issue: 20.02.2020

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides Metal oxides

Oxides of phosphorus

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling Do not get on skin or clothing.



Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Gonadotropin, pregnant mare serum	9002-70-4	TWA	4 μg/m3 (OEB 4)	Internal
		Wipe limit	40 μg/100 cm2	Internal

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance



Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne

levels as low as reasonably achievable.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from

stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type
Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available



Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.



Serum Gonadotrophin Formulation

Date of last issue: 04.12.2024 Version Revision Date: SDS Number: 4.0 14.04.2025 5445454-00009 Date of first issue: 20.02.2020

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Acute oral toxicity : LD50 (Mouse): 120 mg/kg

Acute inhalation toxicity Remarks: No data available

Acute dermal toxicity : Remarks: No data available

administration)

Acute toxicity (other routes of : LD50 (Mouse): > 1,700 mg/kg Application Route: Intravenous

> LD50 (Mouse): > 1,700 mg/kg Application Route: Subcutaneous

LD50 (Rat): 500 mg/kg

Application Route: Intravenous

LD50 (Rat): 500 mg/kg

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available



Serum Gonadotrophin Formulation

Date of last issue: 04.12.2024 Version Revision Date: SDS Number: 4.0 14.04.2025 5445454-00009 Date of first issue: 20.02.2020

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Genotoxicity in vivo Test Type: Cytogenetic assay

Species: Mouse

Application Route: Intraperitoneal injection

Result: positive

Remarks: Not classified due to data which are conclusive

although insufficient for classification.

Carcinogenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Carcinogenicity - Assess-: No data available

ment

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:

Gonadotropin, pregnant mare serum:

Effects on fertility Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: LOAEL: 10 µg/kg Result: Effects on fertility.

Remarks: May cause adverse reproductive effects.

Based on data from similar materials

Effects on fetal development: Remarks: May cause birth defects.

Based on data from similar materials

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on

sexual function and fertility, based on animal experiments.



Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

П

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Gonadotropin, pregnant mare serum:

Species : Rat

NOAEL : 1.5 mg/kg

Application Route : Oral

Exposure time : 3 Days

Symptoms : No adverse effects.

Species : Rat
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 14 Days

Target Organs : Reproductive organs

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Gonadotropin, pregnant mare serum:

Inhalation : Symptoms: Headache, Fatigue, mood swings, altered mental

status, Edema, Allergic reactions, Effects on fertility.

Skin contact : Remarks: May produce an allergic reaction.
Ingestion : Remarks: May be harmful if swallowed.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available



Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for

: Not applicable

producing capsules, tablets and pills.

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 14.04.2025 Date format : dd.mm.yyyy



Serum Gonadotrophin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 4.0
 14.04.2025
 5445454-00009
 Date of first issue: 20.02.2020

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8